The panel voted 20-0 in favor of recommending the vaccine’s broad use in people ages 18 and older, WSJ reported. Michael Kurilla, MD, PhD, a director of clinical innovation with the National Institutes of Health, abstained from the vote. He declined WSJ’s request for comment.
Moderna’s expected approval would make its vaccine the second to be granted emergency use authorization by the FDA. Pfizer’s vaccine became the first Dec. 11.
More articles on pharmacy:
13 drugmakers contracted by Operation Warp Speed in 2020
Some Pfizer COVID-19 vaccine vials contain more doses than expected
30 key leadership changes affecting the pharma industry in 2020
